agent-797
agent-797: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| MiNK Therapeutics, Inc. (INKT) | Phase 1 |
Clinical Trials (1)
A Phase 1 Study of agenT-797 to Treat Moderate to Severe Acute Respiratory Syndrome in COVID-19 Patients
Frequently asked questions
Who is developing agent-797?
agent-797 is being developed by MiNK Therapeutics, Inc..
How many clinical trials involve agent-797?
BioSniper tracks 1 clinical trial involving agent-797.
Get deeper analysis on agent-797
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis